title: Effect of cilostazol in the treatment of acute ischemic stroke in the lenticulostriate artery territory.
abstract: BACKGROUND
  Cilostazol, an inhibitor of phosphodiesterase 3, has various pleiotropic effects besides its antiplatelet activity. This study examined the efficacy of cilostazol for the treatment of acute perforating artery infarction.
  
  
  METHODS
  In this prospective, randomized, open-label, blinded-end point trial, 100 patients with cerebral infarction in the territory of the lenticulostriate arteries were enrolled within 48 h of onset. Patients were randomly treated with both cilostazol and ozagrel for 14 days (n = 50, cilostazol group) or ozagrel alone for 14 days (n = 50, control group). The primary end point was the proportion of favorable outcomes 30 days after randomization as defined by a modified Rankin Scale (mRS) score of 0-2. Secondary end points included the incidence of neurological deterioration (an increase of ≥ 2 on the National Institutes of Health Stroke Scale within 7 days).
  
  
  RESULTS
  Favorable outcomes (mRS scores 0-2) were similar in both groups (81.3 and 82.0% in the cilostazol and control groups, respectively). The incidence of neurological deterioration was lower in the cilostazol group than the control group (12.5 and 16.0%, respectively) with a 21.9% relative risk reduction, although the difference was not statistically significant.
  
  
  CONCLUSIONS
  Cilostazol did not prevent the neurological deterioration of perforating artery infarction.
authors.affiliation: Department of Neuroendovascular Therapy, Kohnan Hospital, Sendai, Japan. rkondoh @ kohnan-sendai.or.jp
authors.forename: Ryushi
authors.initials: R
authors.lastname: Kondo
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: Eisuke
authors.initials: E
authors.lastname: Furui
authors.forename: Ryo
authors.initials: R
authors.lastname: Itabashi
authors.forename: Shoichiro
authors.initials: S
authors.lastname: Sato
authors.forename: Yukako
authors.initials: Y
authors.lastname: Yazawa
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Shimizu
authors.forename: Satoru
authors.initials: S
authors.lastname: Fujiwara
authors.forename: Akira
authors.initials: A
authors.lastname: Takahashi
authors.forename: Teiji
authors.initials: T
authors.lastname: Tominaga
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002545:Brain Ischemia / Q000188:drug therapy*; D000077407:Cilostazol; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008689:Methacrylates / Q000627:therapeutic use; D008875:Middle Aged; D020521:Stroke / Q000188:drug therapy*; D013777:Tetrazoles / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D008689:Methacrylates; D013777:Tetrazoles; C034364:ozagrel; D000077407:Cilostazol